{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:49:09Z","timestamp":1770234549421,"version":"3.49.0"},"reference-count":58,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":922,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1111\/ane.12111","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T17:59:03Z","timestamp":1361469543000},"page":"213-219","source":"Crossref","is-referenced-by-count":30,"title":["Clinical consequences of aspirin and clopidogrel resistance: an overview"],"prefix":"10.1155","volume":"128","author":[{"given":"M. D.","family":"Mijajlovic","sequence":"first","affiliation":[{"name":"Neurology Clinic; Clinical Center of Serbia; School of Medicine; University of Belgrade; Belgrade; Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Shulga","sequence":"additional","affiliation":[{"name":"Department of Neurology; Volyn Regional Clinical Hospital; Lutsk; Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Department of Neurology; Tel-Aviv Sourasky Medical Center - University; Tel-Aviv; Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Covickovic-Sternic","sequence":"additional","affiliation":[{"name":"Neurology Clinic; Clinical Center of Serbia; School of Medicine; University of Belgrade; Belgrade; Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Aleksic","sequence":"additional","affiliation":[{"name":"Neurology Clinic; Clinical Center of Serbia; School of Medicine; University of Belgrade; Belgrade; Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. M.","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Department of Neurology; Tel-Aviv Sourasky Medical Center - University; Tel-Aviv; Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"10.1111\/ane.12111-BIB0001|ane12111-cit-0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/ane.12111-BIB0002|ane12111-cit-0002","doi-asserted-by":"crossref","unstructured":"Brunton L Lazo J Parker K Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill Professional 2005","DOI":"10.1345\/aph.1G685"},{"key":"10.1111\/ane.12111-BIB0003|ane12111-cit-0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-2952(88)90729-0","article-title":"2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism","volume":"37","author":"Grootveld","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/ane.12111-BIB0004|ane12111-cit-0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/15563650600907140","article-title":"Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management","volume":"45","author":"Chyka","year":"2007","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1111\/ane.12111-BIB0005|ane12111-cit-0005","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","article-title":"Aspirin dose for the prevention of cardiovascular disease. A systematic review","volume":"297","author":"Campbell","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/ane.12111-BIB0006|ane12111-cit-0006","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V83.4.885.885","article-title":"Aspirin, platelets, and thrombosis: theory and practice","volume":"83","author":"Roth","year":"1994","journal-title":"Blood"},{"key":"10.1111\/ane.12111-BIB0007|ane12111-cit-0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.2005.00419.x","article-title":"Aspirin resistance in secondary stroke prevention","volume":"113","author":"Berrouschot","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12111-BIB0008|ane12111-cit-0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/ane.12111-BIB0009|ane12111-cit-0009","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/01.CIR.0000142056.69970.DB","article-title":"Terms and conditions. Semantic complexity and aspirin resistance","volume":"110","author":"Hennekens","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0010|ane12111-cit-0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091270007313324","article-title":"Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events","volume":"48","author":"Gengo","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/ane.12111-BIB0011|ane12111-cit-0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","article-title":"Narrative review: aspirin resistance and its clinical implications","volume":"142","author":"Sanderson","year":"2005","journal-title":"Ann Int Med"},{"key":"10.1111\/ane.12111-BIB0012|ane12111-cit-0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/138161206775193064","article-title":"Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance","volume":"12","author":"Macchi","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1111\/ane.12111-BIB0013|ane12111-cit-0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/ane.12111-BIB0014|ane12111-cit-0014","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","article-title":"Aspirin and clopidogrel resistance: an emerging clinical entity","volume":"27","author":"Wang","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/ane.12111-BIB0015|ane12111-cit-0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.thromres.2006.08.009","article-title":"Aspirin resistance: what, why and when?","volume":"119","author":"Shantsila","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/ane.12111-BIB0016|ane12111-cit-0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2006.04.005","article-title":"Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction","volume":"119","author":"Poulsen","year":"2007","journal-title":"Throm Res"},{"key":"10.1111\/ane.12111-BIB0017|ane12111-cit-0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/ane.12111-BIB0018|ane12111-cit-0018","first-page":"289","article-title":"Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease","volume":"39","author":"Kim","year":"2009","journal-title":"Ann Clin Lab Sci"},{"key":"10.1111\/ane.12111-BIB0019|ane12111-cit-0019","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0404.2007.00937.x","article-title":"Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients","volume":"117","author":"Sztriha","year":"2008","journal-title":"Acta Neurol Scan"},{"key":"10.1111\/ane.12111-BIB0020|ane12111-cit-0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1592\/phco.23.5.579.32206","article-title":"Aspirin dosage and thromboxane synthesis in patients with vascular disease","volume":"23","author":"Hart","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1111\/ane.12111-BIB0021|ane12111-cit-0021","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.STR.0000117097.76953.A6","article-title":"Serial urinary 11- dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction","volume":"35","author":"Bruno","year":"2004","journal-title":"Stroke"},{"key":"10.1111\/ane.12111-BIB0022|ane12111-cit-0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"key":"10.1111\/ane.12111-BIB0023|ane12111-cit-0023","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/ane.12111-BIB0024|ane12111-cit-0024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-959300","article-title":"Polypharmacy, compliance and non-rescription medication in patients with cardiovascular disease in Germany","volume":"132","author":"Rottlaender","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1111\/ane.12111-BIB0025|ane12111-cit-0025","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0026|ane12111-cit-0026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.atherosclerosis.2006.11.009","article-title":"Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment","volume":"196","author":"Giusti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1111\/ane.12111-BIB0027|ane12111-cit-0027","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/147323001103900223","article-title":"Functional effect of platelet membrane glycoprotein ia gene polymorphism in the pathogenesis of unstable angina pectoris","volume":"39","author":"Zhao","year":"2011","journal-title":"I Int Med Res"},{"key":"10.1111\/ane.12111-BIB0028|ane12111-cit-0028","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2006.03.005","article-title":"Antithrombotic effects of aspirin based on PLA1\/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease","volume":"119","author":"Dropinski","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/ane.12111-BIB0029|ane12111-cit-0029","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?","volume":"36","author":"Gonzalez-Conejero","year":"2005","journal-title":"Stroke"},{"key":"10.1111\/ane.12111-BIB0030|ane12111-cit-0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2004.10.007","article-title":"The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis","volume":"149","author":"Pamukcu","year":"2005","journal-title":"Am Heart J"},{"key":"10.1111\/ane.12111-BIB0031|ane12111-cit-0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1755-5922.2010.00170.x","article-title":"Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting","volume":"28","author":"Kojuri","year":"2010","journal-title":"Cardiovasc Ther"},{"issue":"2 Suppl.","key":"10.1111\/ane.12111-BIB0032|ane12111-cit-0032","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"10.1111\/ane.12111-BIB0033|ane12111-cit-0033","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/CIRCULATIONAHA.108.857722","article-title":"Can we override clopidogrel resistance?","volume":"119","author":"Pena","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0034|ane12111-cit-0034","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1161\/CIRCULATIONAHA.106.675991","article-title":"Variable platelet response to aspirin and clopidogrel in atherothrombotic disease","volume":"115","author":"Maree","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0035|ane12111-cit-0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0036|ane12111-cit-0036","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12111-BIB0037|ane12111-cit-0037","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Schuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/ane.12111-BIB0038|ane12111-cit-0038","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2009.1249","article-title":"Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?","volume":"302","author":"Bhatt","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/ane.12111-BIB0039|ane12111-cit-0039","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12111-BIB0040|ane12111-cit-0040","unstructured":"Bristol-Myers Squibb\/Sanofi Pharmaceutical Partnership. Plavix (clopidogrel bisulfate) prescribing information http:\/\/products.sanofi-aventis.us\/plavix\/plavix.html"},{"key":"10.1111\/ane.12111-BIB0041|ane12111-cit-0041","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12111-BIB0042|ane12111-cit-0042","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2006.09.014","article-title":"Clopidogrel resistance: role of body mass and concomitant medications","volume":"120","author":"Feher","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1111\/ane.12111-BIB0043|ane12111-cit-0043","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/ane.12111-BIB0044|ane12111-cit-0044","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0045|ane12111-cit-0045","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting","volume":"45","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0046|ane12111-cit-0046","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial","volume":"112","author":"Beckerath","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0047|ane12111-cit-0047","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2006.04.090","article-title":"A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial","volume":"48","author":"Montalescot","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0048|ane12111-cit-0048","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2006.06.049","article-title":"Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting","volume":"48","author":"Cuisset","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12111-BIB0049|ane12111-cit-0049","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000161383.06692.D4","article-title":"Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study","volume":"111","author":"Patti","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0050|ane12111-cit-0050","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/CIRCULATIONAHA.105.536276","article-title":"Loading, pretreatment, and interindividual variability issues with clopidogrel dosing","volume":"111","author":"Bates","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0051|ane12111-cit-0051","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","article-title":"Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention","volume":"100","author":"Lotrionte","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1111\/ane.12111-BIB0052|ane12111-cit-0052","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ahj.2007.01.007","article-title":"Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression","volume":"153","author":"Biondi-Zoccai","year":"2007","journal-title":"Am Heart J"},{"key":"10.1111\/ane.12111-BIB0053|ane12111-cit-0053","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12111-BIB0054|ane12111-cit-0054","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/ane.12111-BIB0055|ane12111-cit-0055","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3949\/ccjm.76.s1.02","article-title":"Novel antiplatelet strategies in acute coronary syndromes","volume":"76","author":"Sabatine","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1111\/ane.12111-BIB0056|ane12111-cit-0056","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/ATVBAHA.108.176388","article-title":"G-protein-coupled receptors as signaling targets for antiplatelet therapy","volume":"29","author":"Smyth","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/ane.12111-BIB0057|ane12111-cit-0057","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1161\/STROKEAHA.109.559567","article-title":"Inflammatory biomarkers of vascular risk as correlates of leukoariosis","volume":"40","author":"Wright","year":"2009","journal-title":"Stroke"},{"key":"10.1111\/ane.12111-BIB0058|ane12111-cit-0058","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association\/american stroke association","volume":"43","author":"Furie","year":"2011","journal-title":"Stroke"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12111\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:46:44Z","timestamp":1671540404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12111","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}